XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.70

-0.8%

Jan 23 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (10777)	7/14/1999 2:12:00 PM
From: Cacaito	Read Replies (2) of 17367

Bluegreen, I read the whole baboon article. The conclusions are a little different. They included the word "maybe". The bactericidal property of bpi was determined by blood culture colony count (nice trick)but they killed the monkeys at 72 hours? The monkey sepsis model is very drastic, infusing lots of bacteria in the veins, it was modified for the bpi experiment. They proof decrease colony counts (potent bactericidal property), they also proof similar endotoxin/lps levels.... but they also proof much lower levels of citokines,tnf,paf (down regulation of the inflammatory pathway)... I agree the main activity is to kill bacteria, but the second property is the one I am investing in Xoma, downregulation of the inflammatory chain. The Lpb patent is a modified lpb to avoid citokine stimulation. Same concept as bpi. They are many peptides antibiotics in the making, but only one bpi, and only one modified lpb (or several all of them from Xoma).

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next